Prescient Therapeutics Limited (ASX:PTX) Financings

Prescient Therapeutics Limited

Financings

RaiseDateIn US dollars
Private placement of fully paid ordinary shares
Closed: A$1.2M raised · A$0.065 a share
Use of proceeds: Strengthen cash position and fund continued development of PTX-100 beyond the first Dose Optimisation Committee review
Sep 29, 2026US$845,261
Share purchase plan of shares
Closed: A$4.8M raised · A$0.065 a share
Use of proceeds: Strengthen cash position and fund continued development of PTX-100 beyond the first Dose Optimisation Committee review
Sep 23, 2026US$3.38M
Share purchase plan of securities under the SPP
Terms changed: share purchase plan
Sep 15, 2026
Share purchase plan of new fully paid ordinary shares
Update: up to A$7M · A$0.065 a share · Reach Markets Pty Ltd
Dealers: Reach Markets Pty Ltd (lead)
Insiders: All eligible directors have participated in the SPP
Use of proceeds: Advance PTX-100 beyond the Dose Optimisation Committee meeting expected in December 2026
Sep 14, 2026US$5.04M

Read by 6ix AI from the company's releases